O	0	10	Diagnostic
O	11	19	accuracy
O	20	22	of
B-intervention	23	33	fiberoptic
I-intervention	34	44	ductoscopy
I-intervention	45	49	plus
I-intervention	50	52	in
I-intervention	53	57	vivo
I-intervention	58	64	iodine
I-intervention	65	73	staining
O	74	77	for
B-condition	78	89	intraductal
I-condition	90	103	proliferative
I-condition	104	111	lesions
O	111	112	.

O	113	119	Iodine
O	120	128	staining
O	129	135	during
O	136	145	endoscopy
O	146	149	has
O	150	154	been
O	155	167	successfully
O	168	172	used
O	173	175	to
O	176	182	detect
O	183	188	early
O	189	202	carcinomatous
O	203	206	and
O	207	219	precancerous
O	220	227	lesions
O	228	230	in
O	231	234	the
O	235	244	esophagus
O	244	245	,
O	246	252	cervix
O	252	253	,
O	254	257	and
O	258	262	oral
O	263	269	cavity
O	269	270	.

O	271	274	The
O	275	284	objective
O	285	287	of
O	288	292	this
O	293	298	study
O	299	302	was
O	303	305	to
O	306	315	determine
O	316	319	the
O	320	330	diagnostic
O	331	339	accuracy
O	340	342	of
O	343	353	fiberoptic
O	354	364	ductoscopy
O	365	366	(
O	366	369	FDS
O	369	370	)
O	371	375	plus
O	376	378	in
O	379	383	vivo
O	384	390	iodine
O	391	399	staining
O	400	403	for
O	404	415	intraductal
O	416	429	proliferative
O	430	437	lesions
O	438	440	of
O	441	444	the
O	445	451	breast
O	451	452	.

O	453	455	We
O	456	465	performed
O	466	474	periodic
O	475	479	acid
O	479	480	-
O	480	486	Schiff
O	487	488	(
O	488	491	PAS
O	491	492	)
O	493	496	and
O	497	499	in
O	500	505	vitro
O	506	512	iodine
O	513	521	staining
O	522	524	on
O	525	527	52
O	528	531	and
O	532	534	64
O	535	544	specimens
O	545	547	of
O	548	554	benign
O	555	562	mammary
O	563	574	hyperplasia
O	574	575	,
O	576	588	respectively
O	588	589	,
O	590	593	and
O	594	596	57
O	597	600	and
O	601	603	53
O	604	613	specimens
O	614	616	of
O	617	623	ductal
O	624	633	carcinoma
O	634	636	in
O	637	641	situ
O	642	643	(
O	643	647	DCIS
O	647	648	)
O	648	649	,
O	650	662	respectively
O	662	663	.

O	664	668	Next
O	668	669	,
O	670	673	FDS
O	674	677	was
O	678	687	performed
O	688	690	on
B-total-participants	691	694	177
B-eligibility	695	704	recurrent
I-eligibility	705	711	nipple
I-eligibility	712	721	discharge
I-eligibility	722	730	patients
O	731	734	who
O	735	739	were
O	740	748	randomly
O	749	756	divided
O	757	761	into
O	762	765	two
O	766	772	groups
O	772	773	.

O	774	777	One
O	778	783	group
O	784	787	was
O	788	794	iodine
O	794	795	-
O	795	803	staining
O	804	809	group
O	810	812	in
O	813	818	which
B-intervention-participants	819	821	92
O	822	830	patients
O	831	835	were
O	836	844	randomly
O	845	853	selected
O	854	856	to
O	857	864	undergo
O	865	871	iodine
O	872	880	staining
O	881	887	during
O	888	891	FDS
O	891	892	,
O	893	896	and
O	897	900	the
O	901	910	remaining
B-control-participants	911	913	85
O	914	918	were
O	919	927	assigned
O	928	930	to
O	931	934	the
B-control	935	942	control
I-control	943	948	group
O	948	949	.

O	950	956	Biopsy
O	957	966	specimens
O	967	969	of
O	970	980	suspicious
O	981	988	lesions
O	989	993	were
O	994	1002	obtained
O	1003	1006	and
O	1007	1016	subjected
O	1017	1019	to
O	1020	1037	histopathological
O	1038	1049	examination
O	1049	1050	.

O	1051	1060	Following
O	1061	1064	PAS
O	1065	1073	staining
O	1073	1074	,
B-outcome	1075	1081	benign
I-outcome	1082	1089	mammary
I-outcome	1090	1101	hyperplasia
I-outcome	1102	1109	lesions
O	1110	1114	were
O	1115	1125	positively
O	1126	1133	stained
O	1133	1134	,
O	1135	1140	while
O	1141	1151	negligible
O	1152	1155	PAS
O	1156	1166	positivity
O	1167	1170	was
O	1171	1179	observed
O	1180	1182	in
O	1183	1186	the
O	1187	1191	DCIS
O	1192	1199	lesions
O	1200	1201	(
O	1201	1202	P
O	1203	1204	<
O	1205	1206	0
O	1206	1207	.
O	1207	1209	05
O	1209	1210	)
O	1210	1211	.

O	1212	1221	Following
O	1222	1224	in
O	1225	1230	vitro
O	1231	1237	iodine
O	1238	1246	staining
O	1246	1247	,
B-outcome	1248	1254	benign
I-outcome	1255	1262	mammary
I-outcome	1263	1274	hyperplasia
I-outcome	1275	1284	specimens
O	1285	1293	appeared
O	1294	1298	dark
O	1299	1304	brown
O	1304	1305	,
O	1306	1313	whereas
O	1314	1318	DCIS
O	1319	1326	samples
O	1327	1335	appeared
O	1336	1349	significantly
O	1350	1357	lighter
O	1358	1360	or
O	1361	1370	unstained
O	1370	1371	.

O	1372	1380	Compared
O	1381	1385	with
O	1386	1389	the
O	1390	1402	pathological
O	1403	1414	examination
O	1415	1422	results
O	1422	1423	,
O	1424	1427	FDS
O	1428	1432	with
O	1433	1439	iodine
O	1440	1448	staining
O	1449	1455	showed
O	1456	1458	an
B-outcome	1459	1468	agreement
I-outcome	1469	1473	rate
I-outcome	1474	1476	in
I-outcome	1477	1480	the
I-outcome	1481	1490	diagnosis
I-outcome	1491	1493	of
I-outcome	1494	1500	ductal
I-outcome	1501	1516	intraepithelial
I-outcome	1517	1526	neoplasia
I-outcome	1527	1528	(
I-outcome	1528	1531	DIN
I-outcome	1531	1532	)
O	1532	1533	,
B-outcome	1534	1545	sensitivity
O	1545	1546	,
B-outcome	1547	1558	specificity
O	1558	1559	,
B-outcome	1560	1568	positive
I-outcome	1569	1579	likelihood
I-outcome	1580	1585	ratio
O	1585	1586	,
B-outcome	1587	1595	negative
I-outcome	1596	1606	likelihood
I-outcome	1607	1612	ratio
O	1612	1613	,
O	1614	1617	and
B-outcome	1618	1624	Youden
I-outcome	1625	1630	index
O	1631	1633	of
B-iv-bin-percent	1634	1636	97
I-iv-bin-percent	1636	1637	.
I-iv-bin-percent	1637	1639	82
I-iv-bin-percent	1639	1640	%
O	1640	1641	,
B-iv-bin-percent	1642	1644	98
I-iv-bin-percent	1644	1645	.
I-iv-bin-percent	1645	1647	83
I-iv-bin-percent	1647	1648	%
O	1648	1649	,
B-iv-bin-percent	1650	1652	83
I-iv-bin-percent	1652	1653	.
I-iv-bin-percent	1653	1655	33
I-iv-bin-percent	1655	1656	%
O	1656	1657	,
B-iv-bin-percent	1658	1659	5
I-iv-bin-percent	1659	1660	.
I-iv-bin-percent	1660	1662	93
O	1662	1663	,
B-iv-bin-percent	1664	1665	0
I-iv-bin-percent	1665	1666	.
I-iv-bin-percent	1666	1669	014
O	1669	1670	,
O	1671	1674	and
B-iv-bin-percent	1675	1676	0
I-iv-bin-percent	1676	1677	.
I-iv-bin-percent	1677	1681	8216
O	1681	1682	,
O	1683	1695	respectively
O	1695	1696	;
O	1697	1700	the
O	1701	1714	corresponding
O	1715	1721	values
O	1722	1725	for
O	1726	1729	FDS
O	1730	1737	without
O	1738	1744	iodine
O	1745	1753	staining
O	1754	1758	were
B-cv-bin-percent	1759	1761	88
I-cv-bin-percent	1761	1762	.
I-cv-bin-percent	1762	1764	24
I-cv-bin-percent	1764	1765	%
O	1765	1766	,
B-cv-bin-percent	1767	1769	89
I-cv-bin-percent	1769	1770	.
I-cv-bin-percent	1770	1772	16
I-cv-bin-percent	1772	1773	%
O	1773	1774	,
B-cv-bin-percent	1775	1777	50
I-cv-bin-percent	1777	1778	.
I-cv-bin-percent	1778	1780	00
I-cv-bin-percent	1780	1781	%
O	1781	1782	,
B-cv-bin-percent	1783	1784	1
I-cv-bin-percent	1784	1785	.
I-cv-bin-percent	1785	1787	78
O	1787	1788	,
B-cv-bin-percent	1789	1790	0
I-cv-bin-percent	1790	1791	.
I-cv-bin-percent	1791	1794	217
O	1794	1795	,
O	1796	1799	and
B-cv-bin-percent	1800	1801	0
I-cv-bin-percent	1801	1802	.
I-cv-bin-percent	1802	1806	3916
O	1806	1807	,
O	1808	1820	respectively
O	1820	1821	.

O	1822	1825	FDS
O	1826	1830	with
O	1831	1837	iodine
O	1838	1846	staining
O	1847	1850	was
O	1851	1859	superior
O	1860	1862	to
O	1863	1875	conventional
O	1876	1879	FDS
O	1880	1883	for
O	1884	1887	the
O	1888	1897	diagnosis
O	1898	1900	of
O	1901	1904	DIN
O	1905	1908	and
O	1909	1911	is
O	1912	1920	valuable
O	1921	1924	for
O	1925	1931	breast
O	1932	1938	cancer
O	1939	1949	prevention
O	1949	1950	.
